Tzank Syndrome (Gestational Trophoblastic Disease)

Overview

Tzank Syndrome is an outdated eponym that historically described a group of rare pregnancy‑related disorders collectively known as Gestational Trophoblastic Disease (GTD). GTD encompasses a spectrum of conditions that arise from abnormal growth of trophoblast cells, the cells that normally develop into the placenta. The most common forms are:

• Hydatidiform mole (complete or partial)
• Invasive mole
• Choriocarcinoma
• Placental‑site trophoblastic tumor

These disorders can range from benign, self‑limited moles to malignant cancers that spread to the lungs, brain, or other organs. Though “Tzank Syndrome” is rarely used in modern literature, many patients still encounter the term when reviewing older medical records or historical articles.

Who Is Affected?

• Women of reproductive age – most cases occur between ages 20‑35, but GTD can develop at any age after menarche.
• Higher incidence in Asian, Hispanic, and Native American populations compared with Caucasian women.
• Occurs after any type of conception: natural pregnancy, in‑vitro fertilization (IVF), or ovulation induction.

Prevalence

Globally, complete hydatidiform mole occurs in about 1 per 1,000 pregnancies, while partial moles are roughly 1 per 500 pregnancies. Malignant GTD (choriocarcinoma, invasive mole, or placental‑site tumor) accounts for <1 % of all GTD cases but is responsible for a disproportionate share of GTD‑related morbidity because of its aggressive nature. In the United States, the overall incidence of GTD is estimated at < 0.5 cases per 1,000 pregnancies, translating to roughly 5,000 new cases annually.¹

Symptoms

Because GTD originates in the uterus, many early symptoms mimic a normal pregnancy. However, certain signs should alert a woman or her clinician to the possibility of a trophoblastic disorder.

• Excessive vaginal bleeding – often dark‑red or brown, may be intermittent or continuous.
• Rapid uterine enlargement – the uterus feels larger than expected for gestational age.
• Severe nausea and vomiting (hyperemesis gravidarum) – frequently more intense than typical morning sickness.
• High‑level human chorionic gonadotropin (hCG) serum – levels may be >100,000 mIU/mL, far exceeding those of a normal pregnancy.
• Preeclampsia‑like symptoms – hypertension, proteinuria, or edema before 20 weeks gestation.
• Pelvic pain or pressure – may indicate invasive growth into the myometrium.
• Gastrointestinal symptoms – early satiety, constipation, or abdominal fullness.
• Respiratory complaints (in malignant GTD) – cough or shortness of breath due to lung metastases.
• Neurologic signs (rare) – headaches, seizures, or visual changes if brain metastasis occurs.
• Accelerated fetal growth or multiple gestations – sometimes confused with twin pregnancy.

Note that many women with a complete mole may have **no symptoms** and are diagnosed incidentally on ultrasound.

Causes and Risk Factors

The exact cause of GTD is not fully understood, but several genetic and environmental factors have been identified.

Genetic Mechanisms

• Complete mole – usually results from fertilization of an empty egg by a single sperm that then duplicates its DNA (46,XX) or by two sperm (46,XX or 46,XY). No fetal tissue is present.
• Partial mole – most commonly occurs when a normal egg is fertilized by two sperm (triploid, 69,XXY, XXX, or XYY). Some fetal tissue may be present.

Identified Risk Factors

• Maternal age under 20 or over 35 years.
• Previous molar pregnancy – risk rises to 1‑2 % after one mole and up to 15 % after two.
• History of miscarriage or infertility treatments (especially ovulation‑inducing drugs).
• Blood group A (some studies suggest a modest association).
• Ethnicity – higher rates in East Asian, South American, and Indigenous North American populations.
• Low socioeconomic status and limited access to prenatal care (delayed diagnosis).

Diagnosis

Prompt recognition is essential because GTD is highly curable when identified early, but can become life‑threatening if it progresses.

Initial Evaluation

1. History & Physical Exam – assessment of bleeding, uterine size, and symptoms.
2. Serum hCG measurement – quantitative β‑hCG is markedly elevated; values >100,000 mIU/mL are typical for complete moles.

Imaging Studies

• Transvaginal ultrasound – classic “snowstorm” or “cluster‑of‑grapes” appearance without a viable embryo (complete mole) or a mixed pattern with a fetus and cystic spaces (partial mole).
• Chest X‑ray or CT – performed when malignancy is suspected to detect lung metastases.
• MRI of brain – reserved for neurologic symptoms.

Pathology

When uterine evacuation is performed, the tissue is sent for histopathologic examination. Key features include:

• Diffuse villous edema, trophoblastic hyperplasia, and absence of embryonic tissue (complete mole).
• Presence of fetal tissue with focal edema (partial mole).
• Invasive growth beyond the uterine wall indicates invasive mole or choriocarcinoma.

Follow‑up Monitoring

After treatment, serial hCG levels are measured weekly until undetectable, then monthly for 6–12 months to ensure remission.

Treatment Options

Treatment is tailored to the specific GTD type, disease stage, and the patient’s desire for future fertility.

1. Uterine Evacuation (First‑Line for Moles)

• Suction curettage – preferred method; performed under ultrasound guidance and general or regional anesthesia.
• Second‑trimester evacuation – rare, may require dilation and evacuation (D&E) or hysterectomy if massive uterine size.

2. Chemotherapy (For Persistent or Malignant GTD)

GTD is one of the most chemosensitive solid tumors.

• Single‑agent therapy – methotrexate or actinomycin‑D, used for low‑risk (FIGO score ≤6) disease.
• Multi‑agent regimens – EMA‑CO (etoposide, methotrexate, actinomycin‑D, cyclophosphamide, vincristine) for high‑risk (FIGO >6) disease.
• Typical treatment duration: 6‑8 cycles, with hCG monitoring to confirm remission.

3. Surgery

• Hysterectomy – considered for women who have completed childbearing, for uncontrolled bleeding, or when disease is confined to the uterus.
• Resection of metastatic lesions – rarely needed because chemotherapy usually eradicates metastases.

4. Radiotherapy

Rarely employed; may be used for brain metastases or resistant pulmonary lesions.

5. Supportive & Lifestyle Measures

• Folic acid supplementation during chemotherapy (prevents methotrexate‑related toxicity).
• Hydration & anti‑emetics to manage chemotherapy side effects.
• Contraception (e.g., hormonal or barrier methods) for at least 12 months after hCG normalization to avoid pregnancy‑related hCG interference.

Living with Tzank Syndrome (Gestational Trophoblastic Disease)

While the diagnosis can be frightening, many patients lead normal lives after treatment. Here are practical tips:

• Regular hCG follow‑up – keep all appointments; a rise in hCG may signal recurrence.
• Emotional support – counseling, support groups, or online communities (e.g., GTD Support Network) help cope with anxiety and grief.
• Nutrition – a balanced diet rich in fruits, vegetables, lean protein, and whole grains supports recovery and overall health.
• Physical activity – light exercise (walking, gentle yoga) after evacuation is safe; avoid heavy lifting for 2‑3 weeks.
• Pregnancy planning – wait at least 6‑12 months after hCG becomes undetectable before trying to conceive; discuss with your obstetrician‑gynecologist.
• Vaccination & infection prevention – chemotherapy can cause neutropenia; practice good hand hygiene and avoid crowds during neutropenic periods.
• Medication review – inform all providers of your GTD history; some drugs (e.g., hormonal contraceptives) are safe, but others may need adjustment.

Prevention

Because GTD originates from abnormal fertilization events, true primary prevention is limited. However, risk can be mitigated:

• Pre‑conception counseling for women with a prior molar pregnancy – close early monitoring with serial hCG.
• Use of single‑embryo transfer (SET) in IVF to reduce multiple‑embryo implantation and abnormal trophoblastic proliferation.
• Management of underlying nutritional deficiencies (e.g., folate, vitamin B12) prior to conception.
• Prompt prenatal care – early ultrasound can detect abnormal gestational sacs before complications develop.

Complications

If GTD is left untreated or inadequately managed, several serious outcomes may arise:

• Persistent GTD – continued hCG elevation after evacuation, requiring chemotherapy.
• Invasive mole – trophoblastic tissue invades the myometrium, causing uterine perforation or severe hemorrhage.
• Metastatic choriocarcinoma – spreads to lungs (most common), brain, liver, or vagina; can be fatal without prompt chemotherapy.
• Hemorrhagic shock – massive vaginal bleeding, especially in large moles.
• Infertility – rare after successful treatment; however, repeated curettage or hysterectomy can affect future fertility.
• Psychological impact – grief, anxiety, or depression related to pregnancy loss and cancer‑type treatment.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. Gestational Trophoblastic Disease. Updated 2023.
2. Mayo Clinic. Hydatidiform mole. Accessed April 2026.
3. National Comprehensive Cancer Network (NCCN). Guidelines for GTD. Version 3.2024.
4. World Health Organization. WHO Classification of Tumors – Trophoblastic Tumors. 2022.
5. Cleveland Clinic. Gestational Trophoblastic Disease Overview. 2024.
6. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 197: Molar Pregnancy. 2023.